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It is likely that the assessment of chemi-
cals for mutagenicity will soon become a
widespread practice, and a large number of
different screening procedures have been
proposed. The subjection of every new
chemical to be released into the environ-
ment to every available test is clearly an
impossible task, and it is necessary for an
understanding of priorities in terms of risk
and benefit to be built into any approach.
The present paper represents an attempt to
frame a protocol for the assessment of new
compounds that is concerned not with the
details of individual tests but rather with
the questions these tests should be designed
to answer and to the evaluation of the an-
swers obtained. It is obviously inherent in
such an approach that a similar assessment
must be made of chemicals already in the
environment, but that is not the purpose of
the present article.
Genetic hazards (with the exception of
nondisjunction and some other chromo-
somal abnormalities) are very different
from toxic hazards, in that there is little or
no likelihood of any feedback from human
epidemiological data. Toxicologists have
stressed (1) that, despite all the animal
testing of the past two decades and before,
most of what we know about toxic hazards
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for man has been derived from clinical or
epidemiological studies on man himself. Un-
fortunately, even the overall mutagenic ef-
fect of chemicals already in the environment
is unlikely to be detectable in man for many
generations unless special monitoring pro-
cedures are instituted such as electrophore-
tic analysis of proteins from umbilical
blood. Laboratory experiments are there-
fore even more important in the evaluation
of genetic risk than in the evaluation of
toxic hazards.
General Principles
In drawing up a framework for the test-
ing and evaluation of chemicals I have been
guided by three general principles.
The first is that no generally mutagenic
chemical should be released into the envi-
ronment or be permitted to be used if there
exists a satisfactory nonmutagenic substi-
tute. Tests are thus required to detect the
mutagenic activity of substances and most
of the procedures so far proposed have had
this object. The phrase, "general mutagenic
chemical," is used specifically to exclude
those substances whose mutagenic action is
confined to a rather special situation such
as formaldehyde when fed to fruit flies.
There is likely to be a hazy line between
such special mutagens and general muta-
gens and some knowledge of the mechanism
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order to be able to judge whether man is
likely to be affected by a particular agent.
The greater value of logical and painstaking
in-depth research over routine testing is as
obvious here as it is with the assessment of
non-genetic toxicological hazards (2).
The second general principle is that the
extent and rigor of the screening proce-
dures should be related to the extent to
which man is likely to be exposed to the
agent. Thus a food additive for widespread
use would need a great deal more attention
than a short-lived no-residue pesticide de-
signed solely for professional horticultural
use.
The third general principle is that muta-
genic substances may be used if the bene-
fits are judged to be great enough to out-
weigh the hazards and if appropriate con-
trols are exercised. The precedent for this
has already been established by ionizing
radiation.
Three-Tier Framework
The proposed framework consists of a
three-tiered evaluation procedure (Fig. 1)
for both detecting mutagens and evaluating
and controlling the hazard from those that
are irreplaceable in use.
The First Tier of in Vitro Tests
The first tier consists of in vitro tests for
the production of gene mutations and chro-
mosomal damage. These tests are performed
by treatment of various organisms with the
chemicals and may be further developed by
treatment in combination with various
chemical agents and biological materials to
mimic the metabolic activation that may
occur within the human body.
The precise tests used need not be re-
garded as immutable and a considerable se-
lection is at present available. As far as the
detection of gene mutations is concerned, it
would seem that bacterial systems are the
most comprehensive and give the most in-
formation at the present time (3-6). Eu-
karyotic systems are, however, available
and lower eukaryotes (e.g., yeasts, and
other fungi), and eventually cultured mam-
malian cells (7-10) may be expected to be
developed to the stage where they can yield
equally valuable information, although not
so cheaply and easily as bacteria. Mitotic
recombination in yeasts has also been sug-
gested as an indicator of nonspecific DNA
damage (11,12). In Drosophila the reces-
sive lethal test is elegant and will detect a
wide spectrum of point mutations. It is,
however, not yet clear how sensitive it is to
point mutations at the molecular level, i.e.,
single base-pair changes, insertions, or de-
letions.
In vitro systems for detecting chromo-
some aberrations at metaphase in cultured
mammalian cells are now well developed,
but it may be almost as convenient-to carry
out the more recent micronucleus and ana-
phase bridge techniques on cultured bone
marrow cells treated in vivo where standard
toxicity tests are also to be carried out.
Theoretically it should be possible to develop
simple tests for detecting agents that give
rise to nondisjunction in eukaryotic micro-
organisms but few have so far been pub-
lished.
It would seem sensible for in vitro tests
to be carried out relatively early in the de-
velopment of a new compound, and since
they are simple and cheap it would seem
desirable to subject to them not only food
additives, pharmaceuticals and pesticides,
but also industrial, cosmetic, agricultural
and household chemicals. Compounds should
be tested at doses well above those to be
used in practice as a substance could be used
in practice at levels well below those detect-
able as mutagenic in the laboratory and
still, in principle, be a significant hazard to
man. Conversely, a valuable compound with
mutagenic activity at high doses might still
be used if subsequent evaluation showed the
hazard at lower doses to be negligible.
It is expected that the majority of chem-
icals will prove to be negative in these first
tier tests, showing that they are not muta-
genic per se. Those that are not likely to be
consumed in any quantity by man (per-
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directly) would be granted a provisional
pass for release. Only those likely to be
consumed in significant quantities (includ-
ing those entering the body directly), such
as food additives or medicines, would pass
on to the second tier of assessment. Those
chemicals giving a positive result would pass
directly to the third tier of evaluation.
The Second Tier of in Vivo Tests
The second tier of tests would relate to
substances designed to be consumed in sig-
nificant amounts usually directly as food ad-
ditives and medicines rather than as con-
taminants. The prime purpose of these tests
is to detect substances that are not muta-
genic in vitro, but are metabolized to an ac-
tive form in viv.o. It is true that by not sub-
mitting indirectly ingested substances to
these tests one may miss a metabolically ac-
tivated mutagen but since the ingested pop-
ulation dose of such substances would be very
small, the population hazard would be min-
ute. It seems far more sensible to concen-
trate in vivo testing on those substances
likely to enter the body in significant quan-
tities.
The host-mediated assay (HMA) (13) is
a test with great potential that will un-
doubtedly be widely used once the possible
interactions of chemicals with the host's re-
sponse to "foreign" cells are properly under-
stood or bypassed by using cells that are not
regarded as foreign. The HMA is only as
good as the cellular mutational system that
is used, and there is a need for more systems
involving the use of mammalian cells. Of
course, the HMA should be accompanied by
in vitro control -tests which would give a
partial duplication of the first tier exam-
ination of this group of compounds.
Production of chromosome aberrations
in vivo may be tested using either the dom-
inant lethal test in the mouse (16) or cyto-
logical analysis of short-term cultured bone
marrow cells.
As with the first tier, substances that are
negative in the tests would be passed for
use, and those that are positive in at least
one test would pass on to the third tier of
evaluation.
_antitative tea,t,s for estimation of mutagenic
risk to man.
Evaluation of risk in relation to permitted






















In vivo detection of




chromosome aberrations Negative Pass
non-disjunction
t entry"
Negative "indirect entry" -- Provisional Pass
TIER 1
In vitro detection of gene mutations
In vitro detection of chromosome aberrations
In vitro detection of mitotic recombination
FIGURE 1. Proposed three-tier framework for mutagenicity screening.
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TIER 3The Third Tier of Quantitative Evaluation
Since most compounds giving a positive
result at one of the first two tiers would
not be essential or unique in their desirable
properties they would be forbidden approval
on the basis of the first general principle.
Some would not be developed further but
others with possibly greater potential value
might well be considered for further de-
velopment with the object of producing a
nonmutagenic derivative.
We are then left with a group of proven
mutagens with potentially great and irre-
placeable social, medical or economic value,
which must encounter the third tier of as-
sessment. To what extent, if any, should
the use of such compounds be permitted in
view of the potential accompanying risk?
Such a decision has already been made for
ionizing radiation so there is nothing new
in a risk-benefit assessment in principle. In
practice, however, future analyses will
differ from that made for ionizing radiation
for a number of reasons. Firstly, no chemi-
cal can be considered in isolation, nor can
chemicals be considered in isolation from
radiation, or indeed from naturally occurr-
ing mutagens. Secondly, assessment of dose
(essential for the evaluation of risk) is like-
ly to be incomparably harder for chemicals
than for ionizing radiations.
There might be a small category of sub-
stances unlikely to be consumed or absorbed
to any extent by the breeding members of
the population as a whole, for example cer-
tain drugs or industrial chemicals. Com-
pounds in this category might be passed for
restricted (and carefully controlled) use
among, for example, elderly patients, those
with incurable disease, and industrial work-
ers. Such use would, of course, depend upon
the evaluation of the carcinogenic risk as
being insignificant. Carcinogenicity evalua-
tion should always be carried out rigor-
ously on any mutagen that is proposed for
use even among a restricted subpopulation.
The important feature that distinguishes
the third from the first two tiers is that
whereas the latter comprise tests for the
detection of mutagenic activity, the evalua-
tion tier requires that a quantitative esti-
mate be made of the mutational risk to man.
This may be an unusual approach to some
who have viewed this problem solely from
a toxicological angle, but it is a necessary
exercise simply because with mutational
risks we are concerned with relatively rare
events in future populations rather than
with observable effects in individual men
and women. One cannot assume that a "no-
effect" dose level exists for mutagens.
The third tier assessors would be charged
with designing the experiments for evaluat-
ing the mutational risk. These experiments
should take into account the properties and
proposed applications of each individual
compound. In considering possible experi-
ments, I shall confine my attention to gene
mutations only although comparable proce-
dures could be devised for chromosomal
damage. In principle, the specific locus test
in the mouse (15) is a very suitable test
that has been successfully used with ioniz-
ing radiation. Unfortunately, except in rare
cases, the doses of mutagenic compounds to
be used in practice would be below the detec-
tion level of the test (a level which is in
fact determined by the enormous cost of the
method). Using higher doses one might be
able to obtain values which could be extra-
polated to lower doses, but it would be a very
laborious business to obtain enough mutants
to have any confidence in the extrapolation.
I would like to make it very clear that nega-
tive results in the specific locus test (or the
HMA test) do not, because of the low sensi-
tivity of these tests, automatically signify
the absence of a hazard for man. A fairly
extensive specific locus experiment may well
not detect significant mutagenesis from a
single- dose of 50 rads of gamma radiation,
and yet some application resulting in a year-
ly dose to man 1000-fold smaller than this
would be regarded with great concern by
the International Commission on Radiolog-
ical Protection.
The HMA might be used if the cellular
system were mammalian and if enough dif-
ferent doses could be used to enable a dose
response -curve to be obtained. Two disad-
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FIGURE 2. Illustration of error resulting from low-
dose extrapolation of a hypothetical host-mediated
assay experiment.
vantages that are immediately apparent are
that the variability of response from one
animal to another in the HMA would re-
sult in very large standard errors, and that
the range of usable doses is often small, the
lower limit being determined by the number
of cells that can be recovered from the ani-
mal and the upper limit by toxic effects of
the chemical on the animal. Thus the dose
response curve would be short and liable to
error; extrapolation back would be ques-
tionable (Figure 2). It is, however, possible
that these problems may be overcome at least
with some substances.
These disadvantages would not exist if the
dose response curve were determined for
mammalian cells in vitro (Fig. 3) ideally
for a number of different loci and for hu-
man as well as rodent cells. Particular at-
tention should be paid to the low-dose re-
gion of the dose response curve and, of
course, any metabolites active in vivo would
also need to be studied. It should be pos-
sible to extrapolate with a reasonable
amount of confidence to population exposure
levels expressed as concentrations in plasma,
blood, ovary or testis. For some substances,
these levels may be directly measurable, for






FIGURE 3. Illustration of error resulting from low-
dose extrapolation of hypothetical in vitro muta-
genicity data.
may be necessary. By means such as these
it should be possible to obtain a quantitative
estimate of mutagenic effect at-,population
exposure doses.
What, then, does one do with such infor-
mation in order to make an evaluation? I
would like to suggest what seems to me to be
the most logical course. The most thorough
assessment has already been- carried -out- for
ionizing radiation and maximum, popula-
tion exposure limits have-been laid down.
Without in any way regarding these as
sacrosanct or immutable one must accept
them as being the best at present available.
I suggest, therefore, that the effect of a
chemical mutagen at proposed population
doses should be expressed in terms of the
dose of ionizing radiation which would pro-
duce the same effect. Such rad-equivalents
(radeq units) would probably differ accord-
ing to the genetic endpoint used; neverthe-
less an overall value should be calculable.
Such a value may then be weighed along-
side the present maximum population lim-
its above the background level for ionizing
radiation (around 0.17 rad/yr) and the pres-
ent actual radiation exposures (around









225,and around 0.035 rad/yr including medical
exposures).
The natural background level is around
0.12 rad/yr. Thus the use of a chemical es-
timated to give a cumulative population ex-
posure to say, >0.1 radeqs/yr might be
deemed to be too hazardous to contemplate,
whereas one giving <0.005 radeqs/yr might
be considered tolerable in view of its advan-
tages and lack of a nonmutagenic substitute.
Substances with intermediate values would be
recognized as possessing a small hazard that
would have to be weighed against the fore-
seeable benefits. Obviously the outcome of a
risk-benefit assessment is likely to vary be-
tween one geographical population and an-
other, and between different subpopulations
within a given population. It would seem
prudent that any mutagenic compound that
is assessed as being sufficiently valuable to
be released should (a) be given a 5-yr license
in the first instance, it being understood that
work on a nonmutagenic derivative would be
given high priority, (b) have its use limited
solely to those situations where its value is
deemed to be great, and (c) have its per-
mitted usage levels carefully and quantita-
tively prescribed.
Obviously the authorized use of any known
mutagen should be accompanied by such
control procedures as may be required to en-
sure that all unnecessary exposure is elim-
inated and that the permitted levels are not
being exceeded.
Concluding Remarks
The assessors' task will be frought with
difficulties (16). One of the more funda-
mental problems will be the determination
of an overall maximum acceptable risk for
the human population. Geneticists are far
from being agreed on the quantitative as-
pect of the deleterious consequences of an
increased rate of gene mutation and the
whole field has developed enormously since
the levels for ionizing radiation were set.
One thing is patently clear: it is logically
absurd and practically foolish to try to deal
with genetic hazards from chemicals and
from radiations in isolation. Ultimately, we
should look forward to the establishment of
an Environmental Genetic Hazards Commis-
sion to consider environmental genetic dam-
age as a whole, in contrast to the piecemeal
assessment of food additives, drugs, pesti-
cides, radiations etc., that exists at present
(if it exists at all).
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